Join The Discussion

 

Ebby Halliday acquires Fort Worth’s Williams Trew

Williams Trew Real Estate of Fort Worth has been acquired by Dallas-based residential real estate brokerage Ebby Halliday Real Estate Inc.

read more >

Meridian Bank Texas parent acquired by UMB Financial for $182.5M

Kansas City, Mo.-based UMB Financial Corp., the parent company of UMB Bank, said Dec. 15 it has signed a definitive agreement to acquire Marquette Financial Companies in an all-stock transaction.

read more >

T&P Warehouse: Historic building remains in limbo as area redevelops

For years, the historic T&P Warehouse on West Lancaster Avenue downtown, built in 1931 to house freight for the Texas Pacific Railway, has sat vacant and deteriorating.

read more >

Cousins Properties to sell 777 Main tower in downtown Fort Worth

Cousins Properties Inc. has confirmed plans to sell the 777 Main office tower in downtown Fort Worth, according to a news release from the Atlanta-based real estate investment firm.

read more >

Glen Garden sale closes, distillery on tap

Firestone & Robertson Distilling Co. closed late Wednesday on its purchase of the historic Glen Garden Country Club in southeast Fort Worth, with plans to convert it into a whiskey distillery and bucolic visitor attraction.

read more >

Nicox, with Fort Worth operations, to acquire Aciex Therapeutics of Boston

Nicox S.A., an international ophthalmic company whose United States operations are based in Fort Worth, will acquire Aciex Therapeutics Inc., a private ophthalmic development pharmaceutical company in Boston, on a cash-free, debt-free basis through a reverse triangular merger.
Under terms of the proposed acquisition, Aciex shareholders will receive an upfront payment of $65 million in the form of 20,627,024 newly issued Nicox shares, plus contingent value rights giving right to shares for a potential additional value of up to $55 million.


The transaction will broaden and strengthen Nicox’s therapeutic development pipeline, which would include two phase 3 candidates, one being developed by Nicox’s partner Bausch + Lomb.
Aciex brings a near-term pipeline of ophthalmic therapeutic product candidates, including one for allergic conjunctivitis.
Aciex was founded in 2007 with technology licensed from Afferent Therapeutics LLC, a spin-out from Ora Inc.


The completion of the acquisition is subject to the approval of Nicox’s shareholders and other customary conditions.
Nicox was founded in 1996 and is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets, and an expanding international presence through partners. The company had a market cap of $271 million as of Feb. 28, 2014, and cash position of $86.1 million as of Sept. 30, 2013. Nicox employs about 134 people worldwide.
Nicox S.A. is listed on Euronext Paris.

Betty Dillard
bdillard@bizpress.net
 

< back

Email   email
hide
TCU/Baylor
Did the College Football Playoff Committee get it right?